Diamond Biotechnology Co., Ltd
Diamond Biotechnology Co., Ltd researches, develops, manufactures, and sells medical equipment and skincare products in Taiwan and internationally. The company offers skin care products under the Timera and Diamond Beauty brands. It also leases medical equipment. Diamond Biotechnology Co., Ltd was founded in 2014 and is based in Taipei, Taiwan.
Diamond Biotechnology Co., Ltd (6815) - Total Liabilities
Latest total liabilities as of June 2025: NT$364.55 Million TWD
Based on the latest financial reports, Diamond Biotechnology Co., Ltd (6815) has total liabilities worth NT$364.55 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Diamond Biotechnology Co., Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Diamond Biotechnology Co., Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Diamond Biotechnology Co., Ltd Competitors by Total Liabilities
The table below lists competitors of Diamond Biotechnology Co., Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Treasury Metals Inc
F:TRC1
|
Germany | €17.76 Million |
|
Wielton S.A.
WAR:WLT
|
Poland | zł1.61 Billion |
|
Mayfield Group Holdings Ltd
AU:MYG
|
Australia | AU$31.26 Million |
|
Jalles Machado S/A
SA:JALL3
|
Brazil | R$5.44 Billion |
|
365330
KQ:365330
|
Korea | ₩34.45 Billion |
|
Dicot Pharma AB
F:KN0
|
Germany | €12.00 Million |
|
Frontier Energy Ltd
AU:FHE
|
Australia | AU$855.45K |
|
CATES ELEKTRIK
IS:CATES
|
Turkey | TL1.14 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Diamond Biotechnology Co., Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Diamond Biotechnology Co., Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Diamond Biotechnology Co., Ltd (2019–2024)
The table below shows the annual total liabilities of Diamond Biotechnology Co., Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$433.28 Million | -4.25% |
| 2023-12-31 | NT$452.52 Million | +38.06% |
| 2022-12-31 | NT$327.77 Million | +22.38% |
| 2021-12-31 | NT$267.83 Million | +30.28% |
| 2020-12-31 | NT$205.58 Million | +11714.89% |
| 2019-12-31 | NT$1.74 Million | -- |